BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones L, Garway-heath DF, Azuara-blanco A, Crabb DP, Garway-heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, Mcnaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as End Points in Clinical Trials? Ophthalmology 2019;126:682-9. [DOI: 10.1016/j.ophtha.2018.09.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Park I, Gale J, Skalicky SE. Health Economic Analysis in Glaucoma. Journal of Glaucoma 2020;29:304-11. [DOI: 10.1097/ijg.0000000000001462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Gazzard G, Kolko M, Iester M, Crabb DP; Educational Club of Ocular Surface and Glaucoma (ECOS-G) Members. A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients. J Glaucoma 2021;30:732-43. [PMID: 34049352 DOI: 10.1097/IJG.0000000000001889] [Reference Citation Analysis]
3 Kuzhuppilly NIR, Pai VH, Daruka R, Jain V, Menon S. A Novel Approach to Measuring Binocular Visual Fields in Glaucoma. J Glaucoma 2021;30:656-60. [PMID: 33813560 DOI: 10.1097/IJG.0000000000001845] [Reference Citation Analysis]
4 Montesano G, Quigley HA, Crabb DP. Improving the Power of Glaucoma Neuroprotection Trials Using Existing Visual Field Data. Am J Ophthalmol 2021;229:127-36. [PMID: 33905747 DOI: 10.1016/j.ajo.2021.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Morris S, Buszewicz M. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technol Assess 2019;23:1-102. [PMID: 31264958 DOI: 10.3310/hta23310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
6 Jelin E, Wisløff T, Jørstad ØK, Heiberg T, Moe MC. Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmol 2019;4:e000353. [PMID: 31673632 DOI: 10.1136/bmjophth-2019-000353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhao C, Li J, Cun Q, Tao Y, Yang W, Tighe S, Zhu Y, Zhong H. Impact of binocular integrated visual field defects on healthy related quality of life in glaucoma. Medicine (Baltimore) 2021;100:e24069. [PMID: 33466164 DOI: 10.1097/MD.0000000000024069] [Reference Citation Analysis]
8 Lazaridis G, Mohamed-Noriega J, Aguilar-Munoa S, Suzuki K, Nomoto H, Garway-Heath DF; United Kingdom Glaucoma Treatment Study Investigators. Imaging Outcomes in Clinical Trials of Treatments for Glaucoma. Ophthalmology 2021;128:1240-2. [PMID: 33373618 DOI: 10.1016/j.ophtha.2020.11.027] [Reference Citation Analysis]
9 Kohnen T, Suryakumar R. Measures of visual disturbance in patients receiving extended depth-of-focus or trifocal intraocular lenses. J Cataract Refract Surg 2021;47:245-55. [PMID: 32818348 DOI: 10.1097/j.jcrs.0000000000000364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Quigley HA. Glaucoma Neuroprotection Trials Are Practical Using Visual Field Outcomes. Ophthalmol Glaucoma 2019;2:69-71. [PMID: 32672606 DOI: 10.1016/j.ogla.2019.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Fenwick EK, Man RE, Aung T, Ramulu P, Lamoureux EL. Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma. Prog Retin Eye Res 2020;76:100801. [PMID: 31676347 DOI: 10.1016/j.preteyeres.2019.100801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 McDonald L, Turnbull P, Chang L, Crabb DP. Taking the strain? Impact of glaucoma on patients' informal caregivers. Eye (Lond) 2020;34:197-204. [PMID: 31767965 DOI: 10.1038/s41433-019-0688-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Taipale J, Mikhailova A, Ojamo M, Nättinen J, Väätäinen S, Gissler M, Koskinen S, Rissanen H, Sainio P, Uusitalo H. Low vision status and declining vision decrease Health-Related Quality of Life: Results from a nationwide 11-year follow-up study. Qual Life Res 2019;28:3225-36. [PMID: 31401749 DOI: 10.1007/s11136-019-02260-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Schakel W, Bode C, Elsman EBM, van der Aa HPA, de Vries R, van Rens GHMB, van Nispen RMA. The association between visual impairment and fatigue: a systematic review and meta-analysis of observational studies. Ophthalmic Physiol Opt 2019;39:399-413. [PMID: 31696537 DOI: 10.1111/opo.12647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
15 Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI From the iStent inject Pivotal Trial. Am J Ophthalmol 2021;229:220-9. [PMID: 33737036 DOI: 10.1016/j.ajo.2021.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]